117 related articles for article (PubMed ID: 18268123)
1. Comprehensive evaluation of ESR2 variation and ovarian cancer risk.
Leigh Pearce C; Near AM; Butler JL; Van Den Berg D; Bretsky P; Conti DV; Stram DO; Pike MC; Hirschhorn JN; Wu AH
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):393-6. PubMed ID: 18268123
[TBL] [Abstract][Full Text] [Related]
2. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
Chen YC; Kraft P; Bretsky P; Ketkar S; Hunter DJ; Albanes D; Altshuler D; Andriole G; Berg CD; Boeing H; Burtt N; Bueno-de-Mesquita B; Cann H; Canzian F; Chanock S; Dunning A; Feigelson HS; Freedman M; Gaziano JM; Giovannucci E; Sánchez MJ; Haiman CA; Hallmans G; Hayes RB; Henderson BE; Hirschhorn J; Kaaks R; Key TJ; Kolonel LN; LeMarchand L; Ma J; Overvad K; Palli D; Pharaoh P; Pike M; Riboli E; Rodriguez C; Setiawan VW; Stampfer M; Stram DO; Thomas G; Thun MJ; Travis RC; Virtamo J; Trichopoulou A; Wacholder S; Weinstein SJ
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1973-81. PubMed ID: 17932344
[TBL] [Abstract][Full Text] [Related]
3. Haplotypes of the estrogen receptor beta gene and breast cancer risk.
; Cox DG; Bretsky P; Kraft P; Pharoah P; Albanes D; Altshuler D; Amiano P; Berglund G; Boeing H; Buring J; Burtt N; Calle EE; Canzian F; Chanock S; Clavel-Chapelon F; Colditz GA; Feigelson HS; Haiman CA; Hankinson SE; Hirschhorn J; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel L; LeMarchand L; Lund E; Palli D; Peeters PH; Pike MC; Riboli E; Stram DO; Thun M; Tjonneland A; Travis RC; Trichopoulos D; Yeager M
Int J Cancer; 2008 Jan; 122(2):387-92. PubMed ID: 17935138
[TBL] [Abstract][Full Text] [Related]
4. Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs.
Benusiglio PR; Lesueur F; Luccarini C; McIntosh J; Luben RN; Smith P; Dunning A; Easton DF; Ponder BA; Pharoah PD
BMC Cancer; 2005 Jul; 5():81. PubMed ID: 16029503
[TBL] [Abstract][Full Text] [Related]
5. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
Canzian F; Kaaks R; Cox DG; Henderson KD; Henderson BE; Berg C; Bingham S; Boeing H; Buring J; Calle EE; Chanock S; Clavel-Chapelon F; Dossus L; Feigelson HS; Haiman CA; Hankinson SE; Hoover R; Hunter DJ; Isaacs C; Lenner P; Lund E; Overvad K; Palli D; Pearce CL; Quiros JR; Riboli E; Stram DO; Thomas G; Thun MJ; Trichopoulos D; van Gils CH; Ziegler RG
BMC Cancer; 2009 Jul; 9():257. PubMed ID: 19640273
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Cancer Causes Control; 2009 Feb; 20(1):47-55. PubMed ID: 18704709
[TBL] [Abstract][Full Text] [Related]
9. Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women.
Paulus JK; Zhou W; Kraft P; Johnson BE; Lin X; Christiani DC
Lung Cancer; 2011 Mar; 71(3):258-63. PubMed ID: 20655613
[TBL] [Abstract][Full Text] [Related]
10. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort.
Cheng I; Stram DO; Penney KL; Pike M; Le Marchand L; Kolonel LN; Hirschhorn J; Altshuler D; Henderson BE; Freedman ML
J Natl Cancer Inst; 2006 Jan; 98(2):123-34. PubMed ID: 16418515
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk.
Gaudet MM; Chanock S; Lissowska J; Berndt SI; Peplonska B; Brinton LA; Welch R; Yeager M; Bardin-Mikolajczak A; Garcia-Closas M
Cancer Res; 2006 Oct; 66(19):9781-5. PubMed ID: 17018638
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the promoter region of ESR2 gene and susceptibility to ovarian cancer.
Schüler S; Lattrich C; Skrzypczak M; Fehm T; Ortmann O; Treeck O
Gene; 2014 Aug; 546(2):283-7. PubMed ID: 24881814
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach.
Lee E; Hsu C; Haiman CA; Razavi P; Horn-Ross PL; Van Den Berg D; Bernstein L; Le Marchand L; Henderson BE; Setiawan VW; Ursin G
Carcinogenesis; 2010 Aug; 31(8):1392-9. PubMed ID: 20547493
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor genotypes and haplotypes associated with breast cancer risk.
Gold B; Kalush F; Bergeron J; Scott K; Mitra N; Wilson K; Ellis N; Huang H; Chen M; Lippert R; Halldorsson BV; Woodworth B; White T; Clark AG; Parl FF; Broder S; Dean M; Offit K
Cancer Res; 2004 Dec; 64(24):8891-900. PubMed ID: 15604249
[TBL] [Abstract][Full Text] [Related]
15. Differential association of ESR1 and ESR2 gene variants with the risk of breast cancer and associated features: A case-control study.
Ghali RM; Al-Mutawa MA; Al-Ansari AK; Zaied S; Bhiri H; Mahjoub T; Almawi WY
Gene; 2018 Apr; 651():194-199. PubMed ID: 29414691
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
[TBL] [Abstract][Full Text] [Related]
17. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
[TBL] [Abstract][Full Text] [Related]
18. Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk.
Terry KL; Tworoger SS; Gates MA; Cramer DW; Hankinson SE
Carcinogenesis; 2009 Dec; 30(12):2042-6. PubMed ID: 19858071
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation in the HSD17B1 gene and risk of prostate cancer.
Kraft P; Pharoah P; Chanock SJ; Albanes D; Kolonel LN; Hayes RB; Altshuler D; Andriole G; Berg C; Boeing H; Burtt NP; Bueno-de-Mesquita B; Calle EE; Cann H; Canzian F; Chen YC; Crawford DE; Dunning AM; Feigelson HS; Freedman ML; Gaziano JM; Giovannucci E; Gonzalez CA; Haiman CA; Hallmans G; Henderson BE; Hirschhorn JN; Hunter DJ; Kaaks R; Key T; Le Marchand L; Ma J; Overvad K; Palli D; Pike MC; Riboli E; Rodriguez C; Setiawan WV; Stampfer MJ; Stram DO; Thomas G; Thun MJ; Travis R; Trichopoulou A; Virtamo J; Wacholder S
PLoS Genet; 2005 Nov; 1(5):e68. PubMed ID: 16311626
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the epidemiological and prognosis significance of ESR2 rs3020450 polymorphism in ovarian cancer.
Feng Y; Peng Z; Liu W; Yang Z; Shang J; Cui L; Duan F
Gene; 2019 Aug; 710():316-323. PubMed ID: 31200086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
